IP Library › Granted Patent US 12,509,716
Granted Patent B2
US 12,509,716 · App. 16/625,586 · Granted Dec 30, 2025

Functional ligands to target vitamin C

Inventor: George W. Jackson (Pearland, TX)
Assignee: BASE PAIR BIOTECHNOLOGIES, INC.
C12Q1/6811C12N15/115C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,509,716
App. No.
16/625,586
Granted
Dec 30, 2025
Kind
B2
Abstract

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as vitamin C or malaria histidine-rich protein II (HRP2).

Claims (2)

1 . An artificial ligand capable of binding to ascorbic acid, comprising a deoxyribonucleic acid having a sequence selected from the group consisting of SEQ ID Nos. 19, 58, 64 and 65.

2 . An artificial ligand capable of binding to ascorbic acid, consisting essentially of a deoxyribonucleic acid having a sequence selected from the group consisting of SEQ ID Nos. 19, 58, 64 and 65.

Continuity (3)
Provisional Application 62522668 · Jun 20, 2017
Provisional Application 62522679 · Jun 20, 2017
Related Publication 20230111624A1 · Apr 13, 2023
References Cited (12)
US 5800992A · Fodor · 1998 [cited by examiner]
US 10201489B2 · Son · 2019 [cited by examiner]
US 20170326058A1 · Son · 2017 [cited by examiner]
CN 104245957A · 2014 [cited by examiner]
WO WO2017150785A1 · 2017 [cited by examiner]
WO WO2017150891A1 · 2017 [cited by examiner]
Wu et al. Novel Aptasensor Platform Based on Ratiometric Surface-Enhanced Raman Spectroscopy, 2017, Anal. Chem., 89, 2852-2858 (Year: 2017). [cited by examiner]
Fischer et al., MassivelyParallel InterrogationofAptamerSequence, StructureandFunction, 2008, PLosOne, 3, e2720, p. 1-9. (Year: 2008). [cited by examiner]
Potty et al., Biophysical characterization of DNA and RNA aptamer interactions with hen egg lysozyme, 2011, Int. J. of Biol. Macromolecules, 48, p. 392-397. (Year: 2011). [cited by examiner]
Alvarez-Martos et al., A DNA sequence obtained by replacement of the dopamine RNA aptamer bases is not an aptamer, Biochemical and Biophysical Research Communications 489 (2017) 381-385) (Year: 2017). [cited by examiner]
Walsh et al., Retention of function in the DNA homolog of the RNA dopamine aptamer, Biochemical and Biophysical Research Communications 388 (2009) 732-735. (Year: 2009). [cited by examiner]
Rohloff et al., Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents, 2014, Molecular Therapy Nucleic Acids, 3, p. 1-13. (Year: 2014). [cited by examiner]